logo
Share SHARE
FONT-SIZE Plus   Neg

Santarus NDA For Inflammatory Bowel Disease Therapy Uceris Accepted By FDA

Santarus Inc. (SNTS: Quote) Wednesday reported that the United States Food and Drug Administration, or FDA, accepted for filing its New Drug Application, or NDA, seeking approval to market Uceris tablets as a therapy to induce remission of mild to moderate active ulcerative colitis. The company anticipates the completion of the FDA's review by mid-October 2012.

The NDA seeks to market Uceris in a 9 milligram, or mg, tablet. Also, Cosmo Pharmaceuticals SpA-owned Cosmo Technologies Ltd., a collaborator in the development of Uceris, is now eligible to $4 million in cash or stock as a milestone payment, Santarus Said.

A form of inflammatory bowel disease, or IBD, ulcerative colitis can cause inflammations and ulcers along the colon, resulting in such effects as diarrhea, frequent bowel movements and bleeding. About 1.4 million Americans suffer from IBDs. Uceris is the trade name for budesonide, which is a corticosteroid with topical anti-inflammatory properties.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Comcast Corp found itself in an unsavory situation after a customer's name on a bill was changed from Ricardo to 'A**hole', ostensibly by a disgruntled employee who tried to get the customer to retain her current cable service and sign a two-year contract. Blockbuster sales of big-screen iPhones during the holiday quarter has helped tech giant Apple Inc. (AAPL) to tie with Samsung to become the world's largest smartphone vendor. Both Apple and Samsung sold 74.5 million smartphones during the December quarter, according to research firm Strategy Analytics.... Toyota Motor Sales, U.S.A., Inc., a unit of Japanese auto giant Toyota Motor Corp. (TYT.L, TM), said it is recalling 52,000 - 2011-2012 Avalon sedans in the U.S. due to a wiring problem that increases risk of fire. The company says cargo in trunk of the affected cars could contact one of the audio...
comments powered by Disqus
Follow RTT